The pharmaceuticals company Glenmark Pharma Ltd introduce medicine for the time with the combination of  Teneligliptin (20mg) and Dapagliflozin (5mg/10mg) for the treatment of adult patients with type two diabetes, especially the ones with comorbidities.

• Hindustan Copper Reports 9% Rise in MIC Output for FY26
• SAIL Shares Slip 0.91% as CMD Amarendu Prakash Steps Down
• Bosch Jumps 12% in Two Sessions on E-Mobility JV
• Latent View Analytics Shares Skyrocket 20% on Deal with Healtheon AI 
• Ola Electric Shares Jump 9% on Roadster X+ Price Cut

‘Zita D’ which contains Teneligliptin (20mg) andDapagliflozin (5 mg/10 mg). This medicine can be consumed by the patient once a day daily as per prescription, which helps to improve glycemic control and prevent complications in adult patients with type two diabetes, especially the ones with comorbidities, as per the statement said.